Cargando…

Involvement of TP53 and TP16 expression in human papillomavirus-associated non-small cell lung cancer

Human papilloma virus (HPV) infection has previously been reported to be associated with TP53 and TP16 expression in Japanese and Taiwanese patients with lung cancer, but data for advanced non-small cell lung cancer (NSCLC) patients is limited. The present study examined the association between HPV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ming, Zhang, Xiao-Lei, Deng, Fang, Qian, Li-Ting, Meng, Shui-Ping, Shan, Wu-Lin, Wang, Bao-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103949/ https://www.ncbi.nlm.nih.gov/pubmed/27900000 http://dx.doi.org/10.3892/ol.2016.5087

Ejemplares similares

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Human papillomavirus DNA and TP53 mutations in lung cancers from butchers.
por: al-Ghamdi, A. A., et al.
Publicado: (1995)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Human Papillomavirus 16 Infection and TP53 Mutation: Two Distinct Pathogeneses for Oropharyngeal Squamous Cell Carcinoma in an Eastern Chinese Population
por: Wang, Zhen, et al.
Publicado: (2016)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
por: Sun, Hao, et al.
Publicado: (2020)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Updates from the TP53 universe
por: Pentimalli, Francesca
Publicado: (2018)

TP53 in Biology and Treatment of Osteosarcoma
por: Synoradzki, Kamil Jozef, et al.
Publicado: (2021)

The Role of TP53 in Adaptation and Evolution
por: Voskarides, Konstantinos, et al.
Publicado: (2023)

Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer
por: Fan, Zhisong, et al.
Publicado: (2022)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability
por: Tam, Benjamin, et al.
Publicado: (2021)

TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
por: Wang, Haiwei, et al.
Publicado: (2022)

TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer
por: Lee, Eung Bae, et al.
Publicado: (2010)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Analysis of Tp53 Codon 72 Polymorphisms, Tp53 Mutations, and HPV Infection in Cutaneous Squamous Cell Carcinomas
por: Loeb, Keith R., et al.
Publicado: (2012)

Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk
por: Eiholzer, Ramona A., et al.
Publicado: (2020)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Significance of TP53 and immune-related genes to prostate cancer
por: Huang, Hang, et al.
Publicado: (2021)

Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer
por: Samulin Erdem, Johanna, et al.
Publicado: (2016)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

TP53 and additional pathways in therapy resistance
por: Lønning, PE
Publicado: (2005)

How TP53 (almost) became an oncogene
por: Weinberg, Robert A
Publicado: (2019)

Spontaneous and inherited TP53 genetic alterations
por: Levine, Arnold J.
Publicado: (2021)

Convergent TP53 loss and evolvability in cancer
por: Mansur, Marcela Braga, et al.
Publicado: (2023)

TP53 alterations in relapsed childhood acute lymphoblastic leukemia
por: Yu, Chih‐Hsiang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p5nm4nup90jsonds69781lv854